Brauchitsch, Sophie von http://orcid.org/0000-0001-8740-9279
Strzelczyk, Adam http://orcid.org/0000-0001-6288-9915
Rosenow, Felix http://orcid.org/0000-0002-3989-7471
Neuhaus, Elisabeth http://orcid.org/0000-0002-7506-0169
Dubinski, Daniel
Steinbach, Joachim P.
Voss, Martin http://orcid.org/0000-0001-8469-5820
Funding for this research was provided by:
Johann Wolfgang Goethe-Universität, Frankfurt am Main
Article History
Received: 29 July 2022
Accepted: 8 September 2022
First Online: 3 November 2022
Declarations
:
: Independent of the study: A. Strzelczyk reports personal fees and grants from Angelini Pharma/Arvelle Therapeutics, Desitin Arzneimittel, Eisai, GW Pharmaceuticals companies, Marinus Pharma, UCB, UNEEG medical, and Zogenix. F. Rosenow reports personal fees from Angelini Pharma/Arvelle Therapeutics, Eisai GmbH, GW Pharmaceuticals/Jazz Pharma, and UCB Pharma and grants from the Detlev-Wrobel-Fonds for Epilepsy Research, the Deutsche Forschungsgemeinschaft (DFG), the Federal Ministry of Education and Research (BMBF), the LOEWE Programme of the State of Hesse, and the European Union. J.P. Steinbach has received honoraria for lectures or advisory board participation or consulting or travel grants from Seagen, Boehringer, Abbvie, Roche, Novocure, Medac and Med-Update. The remaining authors (S. von Brauchitsch, E. Neuhaus, D. Dubinski, M. Voss) declare the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
: Ethics approval was obtained from the ethics committee of the University Hospital Frankfurt; Goethe University (SNO_01–08). This study was performed in accordance with the declaration of Helsinki.
: No individual person’s data is included in this article.